---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-23-000006"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:09:17.060331+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GeneDx (formerly Sema4) eyes 37-40% revenue growth to ~$170-173M in 2022; guides 2023 rev $205-220M

## Summary
- Preliminary pro forma 2022 revenue $170-173M, up 37-40% YoY from $123.7M.
- Pro forma test result volume >180,000 (+23% YoY); adjusted gross margin 38-41% (up from 34%).
- 2023 guidance: revenue $205-220M; cash burn for continuing ops $95-110M; targeting profitability in 2025.
- Name changed to GeneDx Holdings Corp.; common stock begins trading under WGS on Jan 10, 2023.
- CEO highlights combination of GeneDx and Centrellis platforms to accelerate precision medicine.

## SEC filing metadata
- accession: 0001818331-23-000006
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/smfr-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-23-000006
- JSON: https://secwatch.observer/filing/0001818331-23-000006.json
- Plain text: https://secwatch.observer/filing/0001818331-23-000006.txt

## Key facts
- Earnings Releases
  GeneDx Holdings Corp. reported 2022 results: revenue $170-173 million.
  - Period: 2022
  - Revenue: $170-173 million
  - Result: preliminary results
  source text: Preliminary 2022 Financial Results (Unaudited) Excluding revenues and costs from the previously announced exited reproductive health and somatic tumor testing businesses, management expects GeneDx to: • Generate pro forma revenues between $170-173 million in 2022, an approximate 37-40% increase from pro forma $123.7 million in 2021;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm
- Earnings Releases
  GeneDx Holdings Corp. reported full year 2023 results: revenue $205-220 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $205-220 million
  - Guidance: initiated
  - Result: guidance update
  source text: 2023 Guidance (Unaudited) The continuing operations of GeneDx, excluding revenues and costs from exited business activities, are expected to: • Generate revenues between $205-220 million for full year 2023;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm
- Governance Changes
  GeneDx Holdings Corp.: Company changed name from Sema4 Holdings Corp. to GeneDx Holdings Corp. via a certificate of amendment to its certificate of incorporation, effective January 9, 2023 (effective 2023-01-09).
  - Change: charter amendment
  - Effective: 2023-01-09
  source text: Effective as of January 9, 2023, GeneDx Holdings Corp. (the “ Company ”) changed its name from “Sema4 Holdings Corp.” to “GeneDx Holdings Corp.” (the “ Name Change ”) pursuant to a certificate of amendment to its certificate of incorporation (the “ Certificate of Amendment ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm
- Governance Changes
  GeneDx Holdings Corp.: Board adopted amended and restated bylaws effective January 9, 2023, incorporating updates for name change, universal proxy rules, DGCL changes, and other revisions (effective 2023-01-09).
  - Change: bylaw amendment
  - Effective: 2023-01-09
  source text: the Board also approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), effective as of January 9, 2023, in connection with the Name Change as well as the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the DGCL, and a periodic review of the bylaws of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.